Joel Greenblatt Innoviva, Inc. Transaction History

Gotham Asset Management, LLC

$11.5 Billion
Q1 2025

A detailed history of Joel Greenblatt (Gotham Asset Management, LLC) transactions in Innoviva, Inc. stock. As of the latest transaction made, Gotham Asset Management, LLC holds 65,162 shares of INVA stock, worth $1.28 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

65,162

Previous 43,899 48.44%

Holding current value

$1.28 Million

Previous $761,000 55.19%

% of portfolio

0.01%

Previous 0.01%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$17.21 - $18.98 $365,936 - $403,571	21,263 Added 48.44%	65,162 $1.18 Million
Q4 2024 Feb 14, 2025	BUY	$17.35 - $20.32 $206,673 - $242,051	11,912 Added 37.24%	43,899 $761,000
Q3 2024 Nov 14, 2024	BUY	$16.33 - $20.04 $24,805 - $30,440	1,519 Added 4.99%	31,987 $617,000
Q2 2024 Aug 14, 2024	SELL	$14.4 - $16.4 $64,742 - $73,734	-4,496 Reduced 12.86%	30,468 $499,000
Q1 2024 May 15, 2024	BUY	$14.56 - $16.78 $150,987 - $174,008	10,370 Added 42.16%	34,964 $532,000
Q4 2023 Feb 14, 2024	BUY	$12.32 - $16.27 $78,761 - $104,014	6,393 Added 35.12%	24,594 $394,000
Q3 2023 Nov 14, 2023	BUY	$12.37 - $13.89 $26,978 - $30,294	2,181 Added 13.61%	18,201 $236,000
Q2 2023 Aug 14, 2023	SELL	$11.39 - $13.72 $122,146 - $147,133	-10,724 Reduced 40.1%	16,020 $203,000
Q1 2023 May 15, 2023	SELL	$10.73 - $13.6 $140,992 - $178,704	-13,140 Reduced 32.95%	26,744 $300,000
Q4 2022 Feb 14, 2023	SELL	$11.8 - $13.78 $27,045 - $31,583	-2,292 Reduced 5.43%	39,884 $528,000
Q3 2022 Nov 14, 2022	SELL	$11.61 - $15.22 $210,872 - $276,440	-18,163 Reduced 30.1%	42,176 $490,000
Q2 2022 Aug 15, 2022	BUY	$14.32 - $19.88 $137,729 - $191,205	9,618 Added 18.96%	60,339 $891,000
Q1 2022 May 16, 2022	SELL	$15.39 - $20.25 $72,163 - $94,952	-4,689 Reduced 8.46%	50,721 $981,000
Q4 2021 Feb 14, 2022	BUY	$15.91 - $18.72 $270,804 - $318,633	17,021 Added 44.34%	55,410 $956,000
Q3 2021 Nov 15, 2021	BUY	$13.06 - $17.24 $38,853 - $51,288	2,975 Added 8.4%	38,389 $641,000
Q2 2021 Aug 16, 2021	SELL	$11.45 - $13.96 $60,788 - $74,113	-5,309 Reduced 13.04%	35,414 $475,000
Q1 2021 May 17, 2021	SELL	$11.06 - $12.87 $478,002 - $556,228	-43,219 Reduced 51.49%	40,723 $487,000
Q4 2020 Feb 16, 2021	BUY	$9.33 - $12.48 $35,584 - $47,598	3,814 Added 4.76%	83,942 $1.04 Million
Q3 2020 Nov 16, 2020	BUY	$10.33 - $14.49 $233,674 - $327,778	22,621 Added 39.34%	80,128 $837,000
Q2 2020 Aug 13, 2020	SELL	$11.49 - $15.26 $433,896 - $576,263	-37,763 Reduced 39.64%	57,507 $804,000
Q1 2020 May 15, 2020	SELL	$8.11 - $15.23 $94,595 - $177,642	-11,664 Reduced 10.91%	95,270 $1.12 Million
Q4 2019 Feb 14, 2020	SELL	$10.28 - $14.38 $556,579 - $778,561	-54,142 Reduced 33.61%	106,934 $1.51 Million
Q3 2019 Nov 14, 2019	BUY	$10.05 - $14.55 $31,969 - $46,283	3,181 Added 2.01%	161,076 $1.7 Million
Q2 2019 Aug 14, 2019	SELL	$13.1 - $14.95 $921,349 - $1.05 Million	-70,332 Reduced 30.82%	157,895 $2.3 Million
Q1 2019 May 15, 2019	SELL	$13.69 - $20.06 $890,205 - $1.3 Million	-65,026 Reduced 22.17%	228,227 $3.2 Million
Q4 2018 Feb 14, 2019	SELL	$13.96 - $18.26 $1.19 Million - $1.56 Million	-85,209 Reduced 22.51%	293,253 $5.12 Million
Q3 2018 Nov 14, 2018	SELL	$13.63 - $15.7 $1.01 Million - $1.16 Million	-74,040 Reduced 16.36%	378,462 $5.77 Million
Q2 2018 Aug 14, 2018	SELL	$13.44 - $17.59 $1.24 Million - $1.62 Million	-92,367 Reduced 16.95%	452,502 $6.25 Million
Q1 2018 May 15, 2018	SELL	$13.8 - $16.99 $108,826 - $133,983	-7,886 Reduced 1.43%	544,869 $9.08 Million
Q4 2017 Feb 14, 2018	SELL	$11.73 - $14.75 $425,939 - $535,602	-36,312 Reduced 6.16%	552,755 $7.84 Million
Q3 2017 Nov 14, 2017	BUY	$12.06 - $14.12 $7.1 Million - $8.32 Million	589,067	589,067 $8.32 Million

Others Institutions Holding INVA

# of Institutions

256

Shares Held

75M

Call Options Held

2.3K

Put Options Held

2.4K

View Full List

About Innoviva, Inc.

Ticker INVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 69,706,000
Market Cap $1.36B
Description
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a ...

More about INVA

Track Joel Greenblatt's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Gotham Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gotham Asset Management, LLC and Joel Greenblatt with notifications on news.

Account